紫杉醇卡铂单周方案对Ⅲ期胃癌患者的近期疗效和安全性的分析

Analysis of Short-term Efficacy and Safety of Paclitaxel Carboplatin Single-week Regimen in Patients with Stage Ⅲ Gastric Cancer

目的探讨紫杉醇卡铂单周方案对Ⅲ期胃癌患者的近期疗效和安全性。方法选取于该院2017年1—12月收治的Ⅲ期胃癌患者40例,随机分为观察组和对照组,每组20例。观察组采用紫杉醇联合卡铂(TP)单周方案,对照组采用奥沙利铂联合替吉奥(SOX)方案,比较两组化疗药物治疗效果与化疗期间药物不良反应。结果观察组总控制率为100%(20/20),总缓解率为90%(18/20),对照组总控制率为90%(18/20),总缓解率为60%(12/20),观察组总控制率高于对照组,两组相比,无统计学差异(χ~2=0.53.P=0.47);观察组总缓解率高于对照组,两组差异有统计学意义(χ~2=4.80,P=0.03);对照组骨髓抑制、胃肠道反应、恶心的不良反应发生率分别为50%、60%、10%,观察组骨髓抑制、胃肠道反应、恶心的不良反应发生率分别为55%、45%、15%。结论应用紫杉醇卡铂单周方案治疗Ⅲ期胃癌患者具有较好的治疗效果,值得在临床中推广。

Objective To investigate the short-term efficacy and safety of paclitaxel carboplatin single-week regimen in patients with stage Ⅲ gastric cancer. Methods Forty patients with stage Ⅲ gastric cancer admitted to the hospital from January 2017 to December2017 were randomly divided into observation group and control group, with 20 cases in each group. The observation group was treated with paclitaxel plus carboplatin(TP) for one-week regimen, and the control group was treated with oxaliplatin plus tigeolol(SOX) regi-men to compare the effects of chemotherapy with chemotherapy and adverse drug reactions during chemotherapy. Results The total control rate of the observation group was 100%(20/20), the total response rate was 90%(18/20), the total control rate of the control group was 90%(18/20), and the total response rate was 60%(12/20), the total control rate of the observation group was higher than that of the control group, there was no statistical difference between the two groups(χ~2=0.53, P=0.47); the total response rate of the observation group was higher than that of the control group, and the difference between the two groups was significant with statistics significance(χ~2=4.80, P=0.03); the incidence of bone marrow suppression, gastrointestinal reactions, and nausea adverse reactions in the control group were 50%, 60%, and 10%, respectively. The observation group had bone marrow suppression, gastrointestinal reac-tions, and nausea. The incidence of adverse reactions was 55%, 45%, and 15%, respectively. Conclusion The paclitaxel carboplatin single-week regimen has a better therapeutic effect in patients with stage Ⅲ gastric cancer, and it is worthy of promotion in the clinic.